FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1043353362> ?p ?o ?g. }

• W1043353362 endingPage "e1234" @default.
• W1043353362 startingPage "e1234" @default.
• W1043353362 abstract "In Myanmar, hepatitis C virus (HCV) infection prevalence is 2%. A combination therapy of pegylated interferon alfa-2a and ribavirin (PEG-IFNa/RBV) is a standard treatment, but the effect of this antiviral therapy needs evaluation as to determine the efficacy and safety of dual PEG-IFNa/RBV therapy in treating patients infected with HCV in Myanmar. This was a retrospective analysis of data from a single clinic exclusively for gastrointestinal diseases in Yangon, Myanmar. We assessed treatment responses at the defined time points and stratified by genotypes of HCV. We also determined incidences of adverse events (AEs). We investigated independent predictors of sustained virologic response (SVR) in the participants. A total of 362 HCV-infected cases were included in this study. The majority were females (51.7%) with mean age of 47.12 years (±11.6) and noncirrhosis patients (82%). Rapid virologic response (RVR), early virologic response (EVR), end of treatment response (ETR), and SVR 24 weeks after completion of the dual treatment were 50.3% (178/362), 88% (314/357), 80.1% (286/357), and 85.6% (167/195), respectively. The most frequently reported AEs were nausea/anorexia (72.8%) and flu-like symptoms (62.4%). In multivariate analysis, 4 factors were independently associated with SVR; SVR to genotype 3 (odds ratio [OR] 2.4, 95% CI: 1.24–4.62), EVR (OR 0.54, 95% CI: 0.3–0.95), and duration of treatment (OR 1.52, 95% CI: 1.18–1.98). Study limitations were acknowledged. The efficacy and safety of the dual therapy in treating HCV-infected patient in Myanmar was acceptable. We recommend a prospective randomized control trial looking at duration of therapy and rates of achieving SVR, which could significantly impact the care of HCV-infected patients in Myanmar and perhaps other countries as well." @default.
• W1043353362 created "2016-06-24" @default.
• W1043353362 creator A5001866754 @default.
• W1043353362 creator A5013945584 @default.
• W1043353362 creator A5044152115 @default.
• W1043353362 creator A5047799732 @default.
• W1043353362 date "2015-07-01" @default.
• W1043353362 modified "2023-09-24" @default.
• W1043353362 title "Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection" @default.
• W1043353362 cites W1551592846 @default.
• W1043353362 cites W1754449866 @default.
• W1043353362 cites W1894096575 @default.
• W1043353362 cites W1976745213 @default.
• W1043353362 cites W1977300462 @default.
• W1043353362 cites W1979793229 @default.
• W1043353362 cites W1983252677 @default.
• W1043353362 cites W1988544363 @default.
• W1043353362 cites W1989703727 @default.
• W1043353362 cites W2001070009 @default.
• W1043353362 cites W2018446644 @default.
• W1043353362 cites W2027545702 @default.
• W1043353362 cites W2029260575 @default.
• W1043353362 cites W2031485460 @default.
• W1043353362 cites W2044203022 @default.
• W1043353362 cites W2052000792 @default.
• W1043353362 cites W2053748747 @default.
• W1043353362 cites W2065631609 @default.
• W1043353362 cites W2075282196 @default.
• W1043353362 cites W2079187598 @default.
• W1043353362 cites W2089621264 @default.
• W1043353362 cites W2092710527 @default.
• W1043353362 cites W2092858485 @default.
• W1043353362 cites W2106791445 @default.
• W1043353362 cites W2109274399 @default.
• W1043353362 cites W2113864802 @default.
• W1043353362 cites W2123094128 @default.
• W1043353362 cites W2144164191 @default.
• W1043353362 cites W2147248710 @default.
• W1043353362 cites W2151429631 @default.
• W1043353362 cites W2152870084 @default.
• W1043353362 cites W2162967252 @default.
• W1043353362 cites W2164439784 @default.
• W1043353362 cites W2167447251 @default.
• W1043353362 cites W2172262571 @default.
• W1043353362 cites W241424534 @default.
• W1043353362 cites W267117650 @default.
• W1043353362 cites W4319053938 @default.
• W1043353362 doi "https://doi.org/10.1097/md.0000000000001234" @default.
• W1043353362 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4554122" @default.
• W1043353362 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26222859" @default.
• W1043353362 hasPublicationYear "2015" @default.
• W1043353362 type Work @default.
• W1043353362 sameAs 1043353362 @default.
• W1043353362 citedByCount "6" @default.
• W1043353362 countsByYear W10433533622016 @default.
• W1043353362 countsByYear W10433533622017 @default.
• W1043353362 countsByYear W10433533622018 @default.
• W1043353362 countsByYear W10433533622021 @default.
• W1043353362 crossrefType "journal-article" @default.
• W1043353362 hasAuthorship W1043353362A5001866754 @default.
• W1043353362 hasAuthorship W1043353362A5013945584 @default.
• W1043353362 hasAuthorship W1043353362A5044152115 @default.
• W1043353362 hasAuthorship W1043353362A5047799732 @default.
• W1043353362 hasBestOaLocation W10433533621 @default.
• W1043353362 hasConcept C126322002 @default.
• W1043353362 hasConcept C156957248 @default.
• W1043353362 hasConcept C167135981 @default.
• W1043353362 hasConcept C197934379 @default.
• W1043353362 hasConcept C203014093 @default.
• W1043353362 hasConcept C2522874641 @default.
• W1043353362 hasConcept C2776235749 @default.
• W1043353362 hasConcept C2776408679 @default.
• W1043353362 hasConcept C2776455275 @default.
• W1043353362 hasConcept C2776461080 @default.
• W1043353362 hasConcept C2780040827 @default.
• W1043353362 hasConcept C2780580376 @default.
• W1043353362 hasConcept C71924100 @default.
• W1043353362 hasConcept C90924648 @default.
• W1043353362 hasConceptScore W1043353362C126322002 @default.
• W1043353362 hasConceptScore W1043353362C156957248 @default.
• W1043353362 hasConceptScore W1043353362C167135981 @default.
• W1043353362 hasConceptScore W1043353362C197934379 @default.
• W1043353362 hasConceptScore W1043353362C203014093 @default.
• W1043353362 hasConceptScore W1043353362C2522874641 @default.
• W1043353362 hasConceptScore W1043353362C2776235749 @default.
• W1043353362 hasConceptScore W1043353362C2776408679 @default.
• W1043353362 hasConceptScore W1043353362C2776455275 @default.
• W1043353362 hasConceptScore W1043353362C2776461080 @default.
• W1043353362 hasConceptScore W1043353362C2780040827 @default.
• W1043353362 hasConceptScore W1043353362C2780580376 @default.
• W1043353362 hasConceptScore W1043353362C71924100 @default.
• W1043353362 hasConceptScore W1043353362C90924648 @default.
• W1043353362 hasIssue "30" @default.
• W1043353362 hasLocation W10433533621 @default.
• W1043353362 hasLocation W10433533622 @default.
• W1043353362 hasLocation W10433533623 @default.
• W1043353362 hasOpenAccess W1043353362 @default.
• W1043353362 hasPrimaryLocation W10433533621 @default.

• next